During the last three months, 15 analysts shared their evaluations of Bruker (NASDAQ:BRKR), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 5 | 4 | 0 | 2 |
| Last 30D | 0 | 1 | 2 | 0 | 1 |
| 1M Ago | 1 | 0 | 1 | 0 | 0 |
| 2M Ago | 2 | 3 | 1 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 1 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $51.33, a high estimate of $60.00, and a low estimate of $35.00. This upward trend is evident, with the current average reflecting a 8.63% increase from the previous average price target of $47.25.
Exploring Analyst Ratings: An In-Depth Overview
The standing of Bruker among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Patrick Donnelly | Citigroup | Lowers | Neutral | $40.00 | $53.00 |
| Evie Koslosky | Goldman Sachs | Lowers | Sell | $35.00 | $40.00 |
| Dan Brennan | TD Cowen | Lowers | Hold | $43.00 | $53.00 |
| Luke Sergott | Barclays | Lowers | Overweight | $50.00 | $55.00 |
| Subbu Nambi | Guggenheim | Raises | Buy | $58.00 | $53.00 |
| Patrick Donnelly | Citigroup | Raises | Neutral | $53.00 | $40.00 |
| Dan Brennan | TD Cowen | Raises | Hold | $53.00 | $42.00 |
| Subbu Nambi | Guggenheim | Raises | Buy | $53.00 | $45.00 |
| Luke Sergott | Barclays | Raises | Overweight | $55.00 | $45.00 |
| Casey Woodring | JP Morgan | Raises | Overweight | $55.00 | $50.00 |
| Brandon Couillard | Wells Fargo | Raises | Overweight | $55.00 | $48.00 |
| Derik De Bruin | B of A Securities | Raises | Buy | $60.00 | $43.00 |
| Doug Schenkel | Wolfe Research | Announces | Outperform | $60.00 | - |
| Evie Koslosky | Goldman Sachs | Announces | Sell | $40.00 | - |
| Natalya Davies | Rothschild & Co | Announces | Buy | $60.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bruker. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bruker compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Bruker's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Bruker's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Bruker analyst ratings.
All You Need to Know About Bruker
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Understanding the Numbers: Bruker's Finances
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Bruker's revenue growth over a period of 3M has faced challenges. As of 30 September, 2025, the company experienced a revenue decline of approximately -0.45%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -7.25%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.95%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.98%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 0.83, Bruker faces challenges in effectively managing its debt levels, indicating potential financial strain.
The Significance of Analyst Ratings Explained
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
- No comments yet. Be the first to comment!